Maitra B, Szekely E, Gjini K, et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation[J]. Bone Marrow Transplant, 2004, 33(6): 597-604.
[3]
Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade[J]. Br J Haematol, 1997, 97(4): 855-864.
Introna M, Lucchini G, Dander E, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients[J]. Biol Blood Marrow Transplant., 2014, 20(3): 375-381.
[6]
Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor[J]. Biol Blood Marrow Transplant, 2007, 13(11): 1304-1312.
Amorin B, Alegretti AP, Valim V, et al. Mesenchymal stem cell therapy and acute graft-versus-host disease: a review[J]. Human Cell, 2014, 27(4): 137-150.
[9]
Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality[J]. Blood, 2002, 99(10): 3493-3499.
[10]
Amir AL, Hagedoorn RS, van Luxemburg-Heijs SA, et al. Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2012, 18(2): 210-219.
[11]
Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells[J]. Lancet, 2004, 363(9419): 1439-1441.
[12]
Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease[J]. Transplantation, 2006, 81(10): 1390-1397.
[13]
Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study[J]. Lancet, 2008, 371(9624): 1579-1586.
[14]
Prasad VK, Lucas KG, Kleiner GI, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (ProchymalTM) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study[J]. Biol Blood Marrow Transplant, 2011, 17(4): 534-541.
[15]
Kern S, Eichler H, Stoeve J, et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue[J]. Stem Cells, 2006, 24(5): 1294-1301.
